Global use of Haemophilus influenzae type b conjugate vaccine.

Authors :: Ojo LR
O'Loughlin RE
Cohen AL
Loo JD
Edmond KM
Shetty SS
Bear AP
Privor-Dumm L
Griffiths UK
Hajjeh R
Source :: Vaccine [Vaccine] 2010 Oct 08; Vol. 28 (43), pp. 7117-22. Date of Electronic Publication: 2010 Aug 04.
Publication Year :: 2010
Abstract: Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].<br /> (Copyright © 2010. Published by Elsevier Ltd. All rights reserved.)